| New insights into the differentiation of megakaryocytes from hematopoietic progenitors LJ Noetzli, SL French, KR Machlus Arteriosclerosis, thrombosis, and vascular biology 39 (7), 1288-1300, 2019 | 225 | 2019 |
| Platelet-derived extracellular vesicles infiltrate and modify the bone marrow during inflammation SL French, KR Butov, I Allaeys, J Canas, G Morad, P Davenport, ... Blood Advances 4 (13), 3011-3023, 2020 | 86 | 2020 |
| Protease‐activated receptor 4: from structure to function and back again SL French, JR Hamilton British journal of pharmacology 173 (20), 2952-2965, 2016 | 66 | 2016 |
| Inhibition of protease‐activated receptor 4 impairs platelet procoagulant activity during thrombus formation in human blood SL French, JF Arthur, H Lee, WS Nesbitt, RK Andrews, EE Gardiner, ... Journal of Thrombosis and Haemostasis 14 (8), 1642-1654, 2016 | 61 | 2016 |
| Approval of the first protease-activated receptor antagonist: Rationale, development, significance, and considerations of a novel anti-platelet agent SL French, JF Arthur, HA Tran, JR Hamilton Blood reviews 29 (3), 179-189, 2015 | 57 | 2015 |
| Differential signaling by protease-activated receptors: implications for therapeutic targeting TS Sidhu, SL French, JR Hamilton International journal of molecular sciences 15 (4), 6169-6183, 2014 | 42 | 2014 |
| Low-fouling and biodegradable protein-based particles for thrombus imaging T Bonnard, A Jayapadman, JA Putri, J Cui, Y Ju, C Carmichael, ... ACS nano 12 (7), 6988-6996, 2018 | 35 | 2018 |
| A function-blocking PAR4 antibody is markedly antithrombotic in the face of a hyperreactive PAR4 variant SL French, C Thalmann, PF Bray, LE Macdonald, AJ Murphy, ... Blood advances 2 (11), 1283-1293, 2018 | 32 | 2018 |
| Humanizing the Protease-Activated Receptor (PAR) Expression Profile in Mouse Platelets by Knocking PAR1 into the Par3 Locus Reveals PAR1 Expression Is Not … SL French, AC Paramitha, MJ Moon, RA Dickins, JR Hamilton PLoS One 11 (10), e0165565, 2016 | 18 | 2016 |
| The mode of anesthesia influences outcome in mouse models of arterial thrombosis M Sashindranath, SA Sturgeon, S French, DDD Craenmehr, C Selan, ... Research and practice in thrombosis and haemostasis 3 (2), 197-206, 2019 | 14 | 2019 |
| High‐content, label‐free analysis of proplatelet production from megakaryocytes SL French, P Vijey, KW Karhohs, AR Wilkie, LJ Horin, A Ray, B Posorske, ... Journal of Thrombosis and Haemostasis 18 (10), 2701-2711, 2020 | 11 | 2020 |
| Drugs targeting protease-activated receptor-4 improve the anti-thrombotic therapeutic window SL French, JR Hamilton Annals of Translational Medicine 5 (23), 2017 | 10 | 2017 |
| Determination of PAR4 numbers on the surface of human platelets: no effect of the single nucleotide polymorphism rs773902 S Li, V Tarlac, RBI Christanto, SL French, JR Hamilton Platelets 32 (7), 988-991, 2021 | 3 | 2021 |
| Tyrosyl‐tRNA synthetase drives megakaryopoiesis independently of thrombopoietin signaling SL French, KR Machlus Journal of Thrombosis and Haemostasis 17 (4), 564-566, 2019 | 3 | 2019 |
| Perinatal lethality of Par4–/– mice delivered by primiparous dams reveals spontaneous bleeding in mice without platelet thrombin receptor function SL French, JR Hamilton Platelets 29 (2), 196-198, 2018 | 2 | 2018 |
| Improved Inhibition of Protease-Activated Receptor 4 (PAR4) with Function-Blocking Antibodies Provides Equivalent Antithrombotic Activity in the Face of the Hyper-Reactive … SL French, C Thalmann, K Machlus, MA Sleeman, JR Hamilton Blood 130 (Supplement 1), 3603-3603, 2017 | | 2017 |
| Defining the role of protease-activated receptor 4 during thrombosis SL FRENCH Monash University, 0 | | |
